TrialBridgeNCT07896421
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
Recruiting · Not specified · AbbVie · registry updated 2026-10-27
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm. The goal of this observational study is to collect real-world data on treatment patterns, clinical effectiveness, participant characteristics, biomarker testing, and health-related quality of life in participants with FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer receiving mirvetuximab soravtansine. Mirvetuximab soravtansine (MIRV) is an approved antibody-drug conjugate being studied for the treatment of FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer. Adult participants with FRα-positive platinum-resistant cancer who have received 1-3 prior treatment lines and are scheduled to receive MIRV as monotherapy will be enrolled. Approximately 500 participants will be enrolled at sites globally. Participants will receive intravenous infusions of mirvetuximab soravtansine as monotherapy according to the local product label and treating physician's decision. The total study duration per participant may be up to 18 months of follow-up....
Inclusion
- Participants scheduled to be treated with mirvetuximab soravtansine in accordance with the local label, with treatment decision made independently before study enrollment
- Signed informed consent and willingness to comply with study requirements including patient-reported outcome data collection
Exclusion
- Any condition included in the contraindications section of the approved local mirvetuximab soravtansine label
- Participation in a concurrent interventional clinical trial from enrollment throughout the study
- Unwillingness or inability to comply with study requirements